Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $0.02 USD
Change Today +0.0006 / 3.11%
Volume 817.3K
GNBT On Other Exchanges
Symbol
Exchange
OTC US
Stuttgart
As of 8:10 PM 04/17/15 All times are local (Market data is delayed by at least 15 minutes).

generex biotechnology corp (GNBT) Snapshot

Open
$0.02
Previous Close
$0.02
Day High
$0.02
Day Low
$0.02
52 Week High
04/21/14 - $0.04
52 Week Low
12/31/14 - $0.01
Market Cap
15.8M
Average Volume 10 Days
669.3K
EPS TTM
$-0.0011
Shares Outstanding
791.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for GENEREX BIOTECHNOLOGY CORP (GNBT)

Related News

No related news articles were found.

generex biotechnology corp (GNBT) Related Businessweek News

No Related Businessweek News Found

generex biotechnology corp (GNBT) Details

Generex Biotechnology Corporation, a development stage company, engages in the research, development, and commercialization of drug delivery systems and technologies for metabolic and immunological diseases. It focuses on its proprietary technology for the administration of formulations of large molecule drugs to the oral cavity using a hand-held aerosol applicator. The company’s buccal delivery technology and products include Generex Oral-lyn, an insulin formulation administered as a fine spray into the oral cavity using RapidMist hand-held aerosol spray applicator for the treatment of Type 1 and Type 2 diabetes. It is also involved in the research and development of technologies and immunomedicines for the treatment of malignant, infectious, autoimmune, and allergic diseases. In addition, the company is developing immunotherapeutic vaccine AE37 that is under Phase II clinical trial for patients with HER-2/neu positive breast cancer; and synthetic peptide vaccines against avian (H5N1) influenza, as well as vaccines against swine (H1N1) influenza. Further, it is developing synthetic peptide vaccines designed to stimulate a potent and specific immune response against tumors expressing the HER-2/neu oncogene that is in Phase II clinical trial for HER-2/neu positive breast cancer; in two Phase I clinical trials for prostate cancer and against avian influenza; and in Phase I clinical trial for breast or ovarian cancer. The company markets its products through collaborative arrangements with various companies worldwide. Generex Biotechnology Corporation was founded in 1983 and is based in Toronto, Canada.

8 Employees
Last Reported Date: 10/3/14
Founded in 1983

generex biotechnology corp (GNBT) Top Compensated Officers

Chief Executive Officer, President, General C...
Total Annual Compensation: $435.1K
Chief Financial Officer and Principal Account...
Total Annual Compensation: $206.3K
Chief Operating Officer and Secretary
Total Annual Compensation: $206.3K
Compensation as of Fiscal Year 2014.

generex biotechnology corp (GNBT) Key Developments

Generex Biotechnology Corporation Announces Resignation of John P. Barratt as Member of Board of Directors

Generex Biotechnology Corporation announced the resignation of John P. Barratt as a member of the company's Board of Directors. For medical reasons, Mr. Barratt has made the decision to take full retirement from his myriad corporate responsibilities. The resignation from the company’s Board of Directors will take effect on April 30, 2015.

Generex Biotechnology Corporation Provides Update on Buccal Insulin Formulation Enhancement Project

Generex Biotechnology Corporation provided an update on the status of the buccal insulin formulation enhancement project for the company's proprietary Generex Oral-lyn buccal insulin spray product. As previously announced, Generex has engaged the Center for Molecular Design and Preformulations (CMDP) at University Health Network with the goal of enhancing the Generex Oral-lyn formulation to make it more attractive to patients and prospective commercialization partners by increasing the bioavailability of insulin in the product and reducing the number of puffs required to achieve effective prandial metabolic control for patients with diabetes. Generex has entered into a Research Service Agreement with the University of Guelph pursuant to which the University will conduct a study of the relative bioavailability of the enhanced formulation in dogs in the University's Comparative Clinical Research Facility. Dogs proffer ease of administration and the results of the biochemical analyses of the blood are expected to approximate the impact of the product in humans. Allowing a direct comparison with the canine studies the University undertook of the original formulation of Generex Oral-lyn for proof of concept, safety, and toxicity, the new dog study will allow a rapid assessment of the added value of the improved formulation.

Generex Biotechnology Is Considering Various Alternatives

Management of Generex Biotechnology Corp. (OTCPK:GNBT) is seeking various alternatives to ensure that they can meet some of their operating cash flow requirements through financing activities, such as private placement of the common stock, preferred stock offerings and offerings of debt and convertible debt instruments as well as through merger or acquisition opportunities. In addition, management is actively seeking strategic alternatives, including strategic investments and divestitures.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GNBT:US $0.02 USD +0.0006

GNBT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for GNBT.
View Industry Companies
 

Industry Analysis

GNBT

Industry Average

Valuation GNBT Industry Range
Price/Earnings 28.1x
Price/Sales -- Not Meaningful
Price/Book NM Not Meaningful
Price/Cash Flow 7.2x
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GENEREX BIOTECHNOLOGY CORP, please visit www.generex.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.